Karyopharm Therapeutics Inc. 8-K

What Happened

• On February 18, 2026, Karyopharm Therapeutics Inc. held a Special Meeting of Stockholders and announced that stockholders approved an amendment to its Restated Certificate of Incorporation to increase authorized capital stock.
• The Company filed a Certificate of Amendment with the Delaware Secretary of State on February 18, 2026 to effect the change.

Key Details

• The total authorized shares of capital stock were increased from 58,333,333 to 111,000,000.
• Authorized shares of common stock were increased from 53,333,333 to 106,000,000 (an increase of 52,666,667 shares).
• Vote on the Authorized Shares Proposal: For 9,436,123; Against 3,213,329; Abstentions 25,465.
• A separate proposal to allow adjournment for further proxy solicitation (if needed) was also approved: For 10,041,437; Against 2,594,322; Abstentions 39,158. Adjournment was not required because the Authorized Shares Proposal passed.

Why It Matters

• Increasing authorized shares gives the company the legal capacity to issue more stock for purposes such as fundraising, acquisitions, or equity compensation.
• For current investors, the change could lead to dilution if the company issues additional shares; the filing documents the authorization but does not itself issue new shares.
• This event was reported under Item 5.07 of Form 8‑K and is a corporate governance action that affects the company’s equity structure.